EP0809490A4 - USE OF SPECIFIC COMPOUNDS COMPRISING LCK SH2 FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION - Google Patents

USE OF SPECIFIC COMPOUNDS COMPRISING LCK SH2 FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION

Info

Publication number
EP0809490A4
EP0809490A4 EP96905494A EP96905494A EP0809490A4 EP 0809490 A4 EP0809490 A4 EP 0809490A4 EP 96905494 A EP96905494 A EP 96905494A EP 96905494 A EP96905494 A EP 96905494A EP 0809490 A4 EP0809490 A4 EP 0809490A4
Authority
EP
European Patent Office
Prior art keywords
lck
autoimmune diseases
specific compounds
allograft rejection
treat autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96905494A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0809490A1 (en
Inventor
Damien John Dunnington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0809490A1 publication Critical patent/EP0809490A1/en
Publication of EP0809490A4 publication Critical patent/EP0809490A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP96905494A 1995-02-10 1996-02-09 USE OF SPECIFIC COMPOUNDS COMPRISING LCK SH2 FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION Withdrawn EP0809490A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US38638195A 1995-02-10 1995-02-10
US40022095A 1995-03-07 1995-03-07
US49735795A 1995-06-30 1995-06-30
US386381 1995-12-29
US497357 1995-12-29
US400220 1995-12-29
PCT/US1996/001964 WO1996024343A1 (en) 1995-02-10 1996-02-09 Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection

Publications (2)

Publication Number Publication Date
EP0809490A1 EP0809490A1 (en) 1997-12-03
EP0809490A4 true EP0809490A4 (en) 1999-10-20

Family

ID=27409758

Family Applications (2)

Application Number Title Priority Date Filing Date
EP96905494A Withdrawn EP0809490A4 (en) 1995-02-10 1996-02-09 USE OF SPECIFIC COMPOUNDS COMPRISING LCK SH2 FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION
EP96906615A Withdrawn EP0811159A1 (en) 1995-02-10 1996-02-12 A process for identifiying pharmaceutically active agents using an epitope-tagged library

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP96906615A Withdrawn EP0811159A1 (en) 1995-02-10 1996-02-12 A process for identifiying pharmaceutically active agents using an epitope-tagged library

Country Status (10)

Country Link
EP (2) EP0809490A4 (ja)
JP (2) JPH10513474A (ja)
KR (1) KR19980702115A (ja)
AU (1) AU4923796A (ja)
BR (1) BR9607614A (ja)
CA (1) CA2212645A1 (ja)
FI (1) FI973259A (ja)
HU (1) HUP9802078A3 (ja)
NO (1) NO973659L (ja)
WO (1) WO1996024343A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922697A (en) * 1996-10-02 1999-07-13 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
WO2004085406A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
EP1730120A1 (en) 2004-03-23 2006-12-13 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007913A1 (en) * 1992-09-25 1994-04-14 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof
WO1995025118A2 (en) * 1994-03-15 1995-09-21 Trustees Of Tufts University Inhibitors of sh2 domain interactions
US5710129A (en) * 1995-02-23 1998-01-20 Ariad Pharmaceuticals, Inc. Inhibitors of SH2-mediated processes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007913A1 (en) * 1992-09-25 1994-04-14 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof
WO1995025118A2 (en) * 1994-03-15 1995-09-21 Trustees Of Tufts University Inhibitors of sh2 domain interactions
US5710129A (en) * 1995-02-23 1998-01-20 Ariad Pharmaceuticals, Inc. Inhibitors of SH2-mediated processes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9624343A1 *

Also Published As

Publication number Publication date
FI973259A (fi) 1997-10-08
EP0811159A1 (en) 1997-12-10
CA2212645A1 (en) 1996-08-15
AU4923796A (en) 1996-08-27
BR9607614A (pt) 1998-06-09
EP0809490A1 (en) 1997-12-03
NO973659D0 (no) 1997-08-08
JPH10513564A (ja) 1998-12-22
FI973259A0 (fi) 1997-08-07
KR19980702115A (ko) 1998-07-15
WO1996024343A1 (en) 1996-08-15
JPH10513474A (ja) 1998-12-22
NO973659L (no) 1997-10-08
HUP9802078A3 (en) 1999-04-28
HUP9802078A2 (hu) 1998-12-28

Similar Documents

Publication Publication Date Title
PL327312A1 (en) Tricyclic amides useful in inhibiting action of g protecin and in treatment of poliferation-type diseases
AU4859296A (en) Improved fiber filter and methods of use thereof
IL115015A0 (en) Methods of inhibiting demyelinating and desmyelinating diseases
GB9324773D0 (en) Treatment of cellulose
GB2284205B (en) Treatment of agricultural waste
EG21286A (en) Blends of organosillane compounds and their use
ZA96725B (en) Use of phenyclyclohexylcarboxamides
HUP9802078A3 (en) Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection
GB9525918D0 (en) Structure of armrest-driven wheelchair
GB9602162D0 (en) Treatment of waste
GB2283485B (en) Treatment of sludge
ZA961318B (en) Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection
PL322002A1 (en) Variants of human dnase i
EP0833641A4 (en) TREATMENT AND PREVENTION OF PROSTATE DISEASES
AU2845897A (en) Photosensitive elements and their process of use
GB2265366B (en) Treatment of waste
GB9516572D0 (en) Prevention and/or treatment of disease
GB9424333D0 (en) Treatment of aqueous effluents containing fats and oils
GB9526317D0 (en) Improvements in and relating to treatment of effluent sludge
AU7695891A (en) Treatment of autoimmune diseases
AU3163795A (en) Treatment of autoimmune diseases
AU6852896A (en) Diagnosis and treatment of neurological disease
EP0444931A3 (en) Use of 3-oxygermylpropionic acid to treat and prevent diabetes-dependent autoimmune diseases
ZA961785B (en) Treatment of eczema
ZA968902B (en) Methods and compositions for treatment of diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970828

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 970828

RIC1 Information provided on ipc code assigned before grant

Free format text: 6A 61K 31/50 A, 6A 61K 31/435 B, 6A 61K 31/12 B, 6A 61K 31/195 B, 6A 61K 31/165 B, 6A 61K 31/40 B

A4 Supplementary search report drawn up and despatched

Effective date: 19990903

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000623

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1003866

Country of ref document: HK